Derek E. Brundish

TL;DR: Results suggest that [3H]CGP 39653 selectively binds to the NMDA receptor as an antagonist with high affinity and is currently the ligand of choice for labeling theNMDA receptor.

TL;DR: CGP 37849 and CGP 39551 are potent and competitive NMDA receptor antagonists which show significant central effects following oral administration to animals and may find value as tools to elucidate the roles of NMDA receptors in brain function, and potentially as therapeutic agents for the treatment of neurological disorders such as epilepsy and ischaemic brain damage in man.

TL;DR: 3H-CGS 8216 may be a useful ligand for probing the antagonist properties of the benzodiazepine receptor and is likely to exhibit interesting therapeutic effects.

TL;DR: The 3H-substance P binding sites are consistent with those expected for substance P receptors, and the rank order of potency of these substance P-related peptides agrees with that reported for their effects in depolarizing spinal cord neurones.

TL;DR: In animal models of both venous and arterial thrombosis, one inhibitor was shown to produce a dose-dependent inhibition of thrombus formation that in some situations was superior to that of MD-805.